BABA vs HYLN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.
HYLN presents a stark paradox: a stable Piotroski F-Score of 6/9 supported by an exceptionally strong balance sheet (Current Ratio of 10.00 and Debt/Equity of 0.02), contrasted against catastrophic operational performance. Revenue has collapsed by over 52% YoY, and the operating margin is an unsustainable -2165.59%. While the company is not at immediate risk of bankruptcy due to its liquidity, the business model is currently failing to generate meaningful sales or profit, making the current valuation speculative.
Compare Another Pair
Related Comparisons
BABA vs HYLN: Head-to-Head Comparison
This page compares Alibaba Group Holding Limited (BABA) and Hyliion Holdings Corp. (HYLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.